3. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo
Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and
Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94(4):599-610.
4. Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative
neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J
Hematol. 2018;93(12):1474-84.
5. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial
versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood
Cancer J. 2017;7(12):662.
6. T efferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al. Survival and
prognosis among 1545 patients with contempoary polycythemia vera: an international study.
Leukemia. 2013; 27(9):1874-81.
7. Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced
international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J
Haematol. 2020;189(2):291-302.
8. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of
low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-24.
9. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events
and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
10. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al.
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med.
2015;372(5):426-35.
11. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al.
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and
CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet
Haematol. 2020;7(3):e196-e208.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES